Chronic red blood cell (RBC) transfusions and/or erythropoietin (EPO)‐stimulating agents (ESAs; e.g., epoetin‐alfa or ‐beta) are often administered to correct the underlying anemia and to symptomatically manage MDS. The gene discussed is EPO; the disease is myelodysplastic syndrome.